Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Des études de phase 2 sur le lunsekimig ont atteint les critères d’évaluation principaux et secondaires clés dans deux maladies respiratoires
-
Phase 2 studies of lunsekimig, a novel bispecific nanobody, met primary and key secondary endpoints in two chronic respiratory conditions.
-
KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated...
-
Dublin, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The "Bronchiectasis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ...
-
Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "Fair-Market Value Compensation Rates for Pulmonary/Respiratory Diseases KOLs - United States" report has been added to ResearchAndMarkets.com's...
-
Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "Australia Acute Respiratory Distress Syndrome Market Analysis 2025" report has been added to ResearchAndMarkets.com's offering.The Australia Acute...
-
Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ...
-
Positive top-line results for VIBRANT Phase 2 clinical trial of verekitug in CRSwNP with once every 12 week dosing
-
Upstream Bio to Host Conference Call/Webcast to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug in Patients with CRSwNP
-
Dublin, July 04, 2025 (GLOBE NEWSWIRE) -- The "Europe Respiratory Care Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ...